Q: What’s your outlook on this stock ?
5i Research Answer:
ZYME shares have done well, and revenue is rising (from a small base). It has $260M cash but is still losing money, with negative cash flow. It has started more human Phase I trials, and has managed the clinical process well and has brought drugs to market. It is interesting, but much of the current products we think are priced in now, and the future depends on its drug pipeline. This certainly has lots of promise, but many are early stage products. Thus, we would consider it a bit early here, and think buyers have some time.